Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
20/20 BiolabsAIDX +0.72%6 Debt-to-EBITDA is -0.12 as of Mar. 2026. GuruFocus rates AIDX with a GF Score™ of 6/100. The stock has 1 warning sign investors should review. Among 469 Medical Devices & Instruments companies, 20/20 Biolabs ranks worse than 213219.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for 20/20 Biolabs's Debt-to-EBITDA or its related term are showing as below:
AIDX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.39 Med: -0.2 Max: -0.16
Current: -0.3
During the past 3 years, the highest Debt-to-EBITDA Ratio of 20/20 Biolabs was -0.16. The lowest was -0.39. And the median was -0.20.
AIDX's Debt-to-EBITDA is ranked worse than 100% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs AIDX: -0.30
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
20/20 Biolabs Debt-to-EBITDA Related Terms
20/20 Biolabs Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for 20/20 Biolabs's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIDX vs STME, TRIB, VVOS: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, 20/20 Biolabs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
20/20 Biolabs Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 20/20 Biolabs's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where 20/20 Biolabs's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
20/20 Biolabs (AIDX) has a Debt-to-EBITDA of -0.12 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on 20/20 Biolabs. According to the industry distribution chart, 20/20 Biolabs ranks #999999 out of 469 companies in the Medical Devices & Instruments industry.
Is 20/20 Biolabs' Debt-to-EBITDA too high?
20/20 Biolabs' current Debt-to-EBITDA is -0.12. Based on the distribution chart, 20/20 Biolabs ranks #999999 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, 20/20 Biolabs has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does 20/20 Biolabs' Debt-to-EBITDA compare to STME and TRIB?
According to the Medical Devices & Instruments industry distribution chart, 20/20 Biolabs ranks #999999 out of 469 companies for Debt-to-EBITDA. This places 20/20 Biolabs in the lower half of its industry. The industry median Debt-to-EBITDA is 1.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on 20/20 Biolabs. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 20/20 Biolabs's current Debt-to-EBITDA is -0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 20/20 Biolabs stock overvalued right now?
20/20 Biolabs (AIDX) has a current Debt-to-EBITDA of -0.12. The current Debt-to-EBITDA is -0.12. 20/20 Biolabs' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For 20/20 Biolabs (AIDX), the current Debt-to-EBITDA is -0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
6GF Score
Get the complete analysis for AIDX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIDX has been successfully added to your 
